Objective: To assess the activities of biapenem against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis.
Methods: Biapenem/clavulanate (BP/CL) was evaluated for in vitro activity against Mycobacterium tuberculosis (Mtb) multidrug-resistant (MDR) isolates, extensively drug-resistant (XDR) isolates, and the H37RV strain. BP/CL activity against the H37Rv strain was assessed in liquid cultures, in macrophages, and in mice..
Results: BP/CL exhibited activity against MDR and XDR Mtb isolates in liquid cultures. BP/CL treatment significantly reduced the number of colony forming units (CFU) of Mtb within macrophages compared with control untreated infected macrophages. Notably, BP/CL synergized in pairwise combinations with protionamide, aminosalicylate, and capreomycin to achieve a fractional inhibitory concentration for each pairing of 0.375 in vitro. In a mouse tuberculosis infection model, the efficacy of a cocktail of levofloxacin + pyrazinamide + protionamide + aminosalicylate against Mtb increased when the cocktail was combined with BP/CL, achieving efficacy similar to that of the positive control treatment (isoniazid + rifampin + pyrazinamide) after 2 months of treatment.
Conclusion: BP/CL may provide a new option to clinically treat MDR tuberculosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3967/bes2019.033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bloodstream Infection Combined with Thoracic Infection Caused by : A Case Report and Review of the Literature.
Infect Drug Resist
December 2024
Department of Laboratory Medicine, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, People's Republic of China.
Objective: is usually found in urogenital tract infections and is associated with several extra-genitourinary infections, including septic arthritis, bacteremia, and meningitis. Here, we report a rare case of induced bloodstream infection with thoracic inflammation in a surgical patient.
Methods: A 56-year-old male who underwent surgery for multiple pelvic and rib fractures developed fever, pleural effusion, and wound exudation despite receiving prophylactic anti-infection treatment with cefotiam.
Current trend of biapenem susceptibility and disc diffusion breakpoints in Enterobacterales and Pseudomonas aeruginosa.
Indian J Med Microbiol
September 2024
Department of Clinical Microbiology, Christian Medical College, Vellore, India. Electronic address:
Article Synopsis
- Biapenem has been approved for treating complicated urinary tract infections in India, but its effectiveness against ESBL-producing Enterobacterales and Pseudomonas aeruginosa in vitro has not been previously studied.
- The study assessed the susceptibility of various isolates to biapenem using broth microdilution and identified resistance genes through multiplex PCR.
- Results showed biapenem's in-vitro activity is comparable to meropenem against resistant E. coli, K. pneumoniae, and P. aeruginosa, with a recommended testing concentration of 10 μg for accurate results.
In vitro activity, pharmacodynamic profile and dose optimization of biapenem against NDM and OXA-48-like carbapenemase-producing Klebsiella pneumoniae: A multicentre study in Thailand.
J Glob Antimicrob Resist
June 2024
Department of Pharmaceutical Care, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand; Pharmaceutical Initiative for Resistant Bacteria and Infectious Diseases Working Group [PIRBIG], Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Thailand. Electronic address:
Background: Biapenem (BIPM) exhibited a less efficient substrate for various metallo-β-lactamase (MBL) than other carbapenems.
Objective: We aimed to evaluate in vitro susceptibility data of BIPM and optimal dose based on Monte Carlo simulation to extend treatment options.
Methods: We collected 192 carbapenem-resistant Klebsiella pneumoniae (CRKP) clinical isolates from unique patients among multicentres in Thailand, from June 2019 to March 2023.
Preferential meropenem absorption activated by 1α,25-dihydroxyvitamin D and shared with foscarnet, a phosphate transporter substrate, in the rat ileum.
Drug Metab Pharmacokinet
April 2024
Department of Pharmaceutics, School of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari, Tobetsu, Hokkaido, 061-0293, Japan. Electronic address:
Meropenem (MEPM) is used for the treatment of serious infectious diseases solely as. INJECTABLE: Therefore, the development of an oral formulation would expand its clinical utility. To this end, an exact understanding of the absorption characteristics of MEPM is essential.
View Article and Find Full Text PDF[ activity of β-lactamase inhibitors avibanvctam and relebactam in combination with β-lactams against multidrug-resistant and mutations of resistance genes].
Zhonghua Jie He He Hu Xi Za Zhi
August 2023
Henan Province Center for Disease Control and Prevention, Zhengzhou 450016, China.
To evaluate the activity of six β-lactams in combination with three β-lactamase inhibitors against mycobacterium tuberculosis(MTB) . A total of 105 multidrug-resistant tuberculosis (MDR-TB) strains from different regions of Henan province from January to September 2020 were included in this study. Drug activity of six β-lactams (biapenem, meropenem, imipenem, doripenem, ertapenem and tebipenem) alone or in combination with β-lactamase inhibitors (clavulanic acid, avibactam and relebactam) was examined by minimum inhibitory concentration method (MICs) against 105 clinical isolates.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!